Novel CAR T cell therapy moves into clinical studies

MedicalXpress | ماي 15, 2026

The University of Texas MD Anderson Cancer Center and CTMC, a joint venture between UT MD Anderson and Resilience, today announced that the Food and Drug Administration (FDA) has issued a 'safe to proceed' for the Investigational New Drug (IND) application for a novel chimeric antigen receptor (CAR) T cell therapy.